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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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The atmosphere in the packed San Diego Huntington’s disease support
group meeting room on the evening of October 28 was both somber and
electric with anticipation.
Flanked by loved ones, HD-affected individuals struggled with involuntary
movements and a hampered ability to communicate, providing stark
evidence of the disease’s unrelenting attack on minds and bodies.
For asymptomatic HD gene carriers like me, they represented our future if
scientists don’t soon find a way to stop the inevitable, devastating
symptoms. I always leave these monthly meetings deeply unsettled and
unable to sleep soundly.
At the front of the room, a key player in the effort to develop effective
treatments, Jody Corey-Bloom, M.D., Ph.D., explained how the local firm
Isis Pharmaceuticals, Inc., had successfully run the first ever safety test of
its unique type of drug in patients suffering from a neurological disorder,
in this case, amytrophic lateral sclerosis (ALS), also known as Lou Gehrig’s
disease or motor neuron disease. The results were published in the May
2013 issue of the journal Lancet Neurology. Isis is developing an HDgene-silencing drug in partnership with the pharmaceutical giant Roche.
“I realize you guys are just tired of waiting (for treatments),” Dr. CoreyBloom told the audience of some 50 people. “But I think Isis is really in a
good position right now (to get their HD drug into a clinical trial)….
They’ve got lots of money, with Roche’s kind of support. I think that
they’re feeling comfortable about the fact that they were able to do this.”
None of the ALS trial participants experienced adverse effects from the Isis
drug, Dr. Corey-Bloom said.
Although Dr. Corey-Bloom pointed out that the very small dose of the Isis
drug, an artificial form of DNA known as an antisense oligonucleotide
(ASO), did not affect the ALS symptoms, the evidence from the trial of
safety and patients’ tolerance for the drug helped paved the way for
additional tests to examine efficacy.
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It also set the stage for the planned Isis-Roche HD clinical trial, tentatively
scheduled to start sometime in the next 18 months. The project has the
support of the CHDI Foundation, Inc., the non-profit virtual biotech firm
dedicated to finding treatments for HD. (Click here to read more.)
Surveying the field
The San Diego support group had convened to hear Dr. Corey-Bloom’s
annual HD research update, usually the best attended meeting of the year.
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The diminutive but tireless neurologist dedicated the first half of her 85minute presentation to HD research conducted locally, including projects
at the unit she directs, the Huntington’s Disease Society of America Center
of Excellence for Family Services and Research at the University of
California, San Diego. These studies have mainly focused on ways to
measure the onset and progression of the disease – essential for gauging
the efficacy of drugs tested in clinical trials. (Click here for an example.)
In addition, Dr. Corey-Bloom surveyed some of the clinical trials set to
begin soon, including a phase II trial for a phosphodiesterase inhibitor (a
kind of “Viagra for the brain”) planned by Omeros Corporation.
Dr. Corey-Bloom also announced that she’s seeking funding from the
National Institutes of Health (NIH) to conduct a clinical trial in HD
patients of an already widely used non-HD drug shown to increase BDNF
(brain derived neurotrophic factor), a kind of “fertilizer” for the brain. HD
patients have insufficient BDNF, which could cause cell death in the deep
structures of the brain where the disease is thought to begin, she
explained.
“I stumbled across it mainly because I was just reading some other things,”
said Dr. Corey-Bloom, who declined to identify the drug until funding is in
place and the drug’s manufacturer agrees to participate in the research. “I
said, ‘Ooh! Wow!’ It’s such a great story. It’s been keeping me up at night
thinking about it. We will get it going. First with animals, then with
people.”
Her project collaborator is Beth Thomas, Ph.D., of the Scripps Research
Institute in San Diego.
You can watch Dr. Corey-Bloom’s presentation and the Q & A in the videos
below.

Advances in Huntington's Disease
Treatments: A Presentation by Dr.
Jody Corey-Bloom (Part I)
from Gene Veritas

1:24:25

Advances in Huntington's Disease Treatments: A Presentation by Dr. Jody
Corey-Bloom (Part I) from Gene Veritas on Vimeo.
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Advances in Huntington's Disease
Treatments: A Presentation by Dr.
Jody Corey-Bloom (Part II)
from Gene Veritas

26:28

Advances in Huntington's Disease Treatments: A Presentation by Dr. Jody
Corey-Bloom (Part II) from Gene Veritas on Vimeo.
Comfort and risk versus efficacy
As potentially one of the best treatments for HD because of its genetic
approach, the Isis ASOs for HD commanded the most attention from both
Dr. Corey-Bloom and the audience.
As Isis and Roche move ever closer to the long-awaited trial – Isis had first
hoped to start a Phase I several years ago – crucial questions of drug
delivery and dosage have gained increasing attention.
Dr. Corey-Bloom’s observations highlighted a delicate issue: the tensions
between patient comfort/risk and drug efficacy.
She identified a key question: will enough of the ASO travel through the
cerebral spinal fluid (CSF) from the patient’s back, where Isis plans to
introduce the drug via a spinal tap, all the way to the brain?
A certain amount of the CSF naturally travels up the spinal column and
over the brain, Dr. Corey-Bloom explained, but some of the ASO
medication could be lost along the way.
“I think one of the big issues is how to inject,” she said. “I actually said the
last time I was at Isis that they just need to put in an Ommaya
reservoir and just inject it that way…. We do lots of chemotherapy for
people that have brain cancer or brain infections. We put this little plastic
disk into this space at the bottom of the brain [she indicated behind her
ear], and then if people need to have anti-fungal medication … or cancer
chemotherapies, we inject right into that little bubble, and it goes right
into the cerebral spinal fluid.”
Dr. Corey-Bloom said that Isis scientists wanted to avoid the extra risk and
cost of the Ommaya insertion, which, although done in just about 15
minutes and with minimal sedation, requires an operating room.
“It’s so much easier to be doing it through a spinal tap in the back than to
be doing ‘brain surgery,’ which is what they kept calling it,” she continued,
referring to the fact that the spinal tap doesn’t require an operation.
However, she affirmed that opting for the “more involved” Ommaya
reservoir could bring better trial results.
“At least we’ll know that the medicine is getting in right up there, as
opposed to way down here,” she said, pointing to her back. “If it doesn’t
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work, or if it doesn’t work as well as it should, we’ll be kind of wondering if
maybe should have put it in a lot closer to where we need it to go.”
Proactive families
The support group/physician connection underscores the critical role of
proactive patient and family participation in research and clinical trials.
The audience always follows up with questions that focus on the heart of
the matter: when and how clinical trials and treatments will bring the
promise of ameliorating HD.
Referring to Dr. Corey-Bloom’s discussion of the critical use of MRI scans
in HD research, one group member asked whether a similar magnetic force
or some electronic structure could be used to “drive” the Isis ASO drug up
to the brain.
That’s “really kind of clever,” she responded, noting that she would present
the idea to Isis when she meets with company researchers on November
20 to discuss the clinical trial program, including the option of the
Ommaya reservoir. Her job, she said, is to bring home the clinical reality of
HD to scientists who spend most of their time in the lab.
Future benefits
Dr. Corey-Bloom also will urge Isis to go beyond the standard safety and
tolerability measures of a Phase I trial to consider measuring efficacy, too,
she added. “They’re going to want to do a Phase I trial that is only safety
and tolerability…. I think that misses your opportunity to do exploratory
efficacy measures.”
The Food and Drug Administration permits this type of exploratory work
in Phase I, she noted.
Isis and Roche could not draw official conclusions from such exploratory
data, she said, but it could give the scientists “some idea of what to use” in
the potential Phases II and III of the trial and beyond.
Looking to the future could help broaden the application of the drug to
people in different stages of HD – including presymptomatic gene carriers
like me for whom an effective treatment would prevent onset and
ultimately make HD a thing of the past.
Posted by Gene Veritas at 9:50 PM
Labels: ALS , antisense oligonucleotide , BDNF , CHDI , clinical trials , CSF , gene
carrier , Huntington's disease , Isis , Jody Corey-Bloom , neurologist , Ommaya
reservoir , risk , Roche , support group , symptoms , treatments

1 comment:
Anonymous said...
Why did the author leave out references to other promising
clinical drug candidates for treatment of HD? The FDA, for
example, just granted "Orphan Drug" status to OMS-824, a
PDE-10 inhibitor that will soon undergo Phase II trials in
patients (by YE 2013). Here is the story:
http://investor.omeros.com/phoenix.zhtml?c=219263&p=irolnewsArticle_Print&ID=1859632&highlight=
12:32 PM, November 04, 2013
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